-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$38.60244.95% Upside
UroGen Pharma Ltd. Frequently Asked Questions
-
What analysts cover UroGen Pharma Ltd.?
UroGen Pharma Ltd. has been rated by research analysts at EF Hutton, Evercore ISI, Oppenheimer, H.C. Wainwright, Goldman Sachs in the past 90 days.